研報掘金丨中郵證券:維持中寵股份“買入”評級,多品牌系列驅動頑皮穩健增長
中郵證券研報指出,中寵股份618預售反饋積極,多品牌系列驅動頑皮穩健增長。目前頑皮下有經典系列、小金盾、精準餵養3個系列,細分系列對應不同客羣、卡位不同價格帶。經典系列產品結構持續優化,佔比進一步提升,小金盾在年初設定為階段性試水目標,但通過精準營銷和促銷活動、實際表現超出預期,全年預期將貢獻顯著增量。公司研發互動機制持續完善,公司成立創新研發部門專門對接產品部和研發部,將最新產品動態、行業趨勢跟進並彙總,強化研發投入,深化功能性產品佈局、提升品牌價值,在市場競爭中鞏固自身優勢。維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.